Donald P. Braun Acquires 25,000 Shares of Imunon, Inc. (NASDAQ:IMNN) Stock

Imunon, Inc. (NASDAQ:IMNN) Director Donald P. Braun bought 25,000 shares of the firm’s stock in a transaction dated Tuesday, August 20th. The shares were acquired at an average price of $1.18 per share, for a total transaction of $29,500.00. Following the completion of the transaction, the director now directly owns 25,597 shares in the company, valued at approximately $30,204.46. This represents a 4,187.60 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Imunon Price Performance

Imunon stock opened at $0.90 on Thursday. Imunon, Inc. has a 1-year low of $0.48 and a 1-year high of $3.65. The company’s 50-day moving average is $0.87 and its 200 day moving average is $1.01. The firm has a market capitalization of $13.06 million, a P/E ratio of -0.48 and a beta of 2.04.

Imunon (NASDAQ:IMNN) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.03. During the same period in the prior year, the business earned ($0.37) EPS. Research analysts anticipate that Imunon, Inc. will post -1.68 earnings per share for the current fiscal year.

Analysts Set New Price Targets

IMNN has been the topic of a number of recent research reports. D. Boral Capital restated a “buy” rating and set a $29.00 price objective on shares of Imunon in a research report on Friday, January 24th. HC Wainwright restated a “buy” rating and issued a $12.00 price target on shares of Imunon in a research report on Thursday, December 19th.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.